Literature DB >> 8862515

Elevated venous glutamate levels in (pre)catabolic conditions result at least partly from a decreased glutamate transport activity.

V Hack1, O Stütz, R Kinscherf, M Schykowski, M Kellerer, E Holm, W Dröge.   

Abstract

Abnormally high postabsorptive venous plasma glutamate levels have been reported for several diseases that are associated with a loss of body cell mass including cancer, human/simian immunodeficiency virus infection, and amyotrophic lateral sclerosis. Studies on exchange rates in well-nourished cancer patients now show that high venous plasma glutamate levels may serve as a bona fide indicator for a decreased uptake of glutamate by the peripheral muscle tissue in the postabsorptive period and may be indicative for a precachectic state. High glutamate levels are also moderately correlated with a decreased uptake of glucose and ketone bodies. Relatively high venous glutamate levels have also been found in non-insulin-dependent diabetes mellitus and to some extent also in the cubital vein of normal elderly subjects, i.e., in conditions commonly associated with a decreased glucose tolerance and progressive loss of body cell mass.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862515     DOI: 10.1007/bf00207511

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  45 in total

1.  The glucose metabolism of patients with malignant disease and of normal subjects as studied by means of an intravenous glucose tolerance test.

Authors:  P A MARKS; J S BISHOP
Journal:  J Clin Invest       Date:  1957-02       Impact factor: 14.808

Review 2.  A review of the control of breathing during exercise.

Authors:  J H Mateika; J Duffin
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1995

Review 3.  Metabolic approaches to cancer cachexia.

Authors:  D H Lawson; A Richmond; D W Nixon; D Rudman
Journal:  Annu Rev Nutr       Date:  1982       Impact factor: 11.848

4.  Gluconeogenesis from alanine in patients with progressive malignant disease.

Authors:  C Waterhouse; N Jeanpretre; J Keilson
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

5.  T4+ cell numbers are correlated with plasma glutamate and cystine levels: association of hyperglutamataemia with immunodeficiency in diseases with different aetiologies.

Authors:  H P Eck; T Mertens; H Rosokat; G Fätkenheuer; C Pohl; M Schrappe; V Daniel; H Näher; D Petzoldt; P Drings
Journal:  Int Immunol       Date:  1992-01       Impact factor: 4.823

6.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

Review 7.  Cancer cachexia in man: a review.

Authors:  A J Strain
Journal:  Invest Cell Pathol       Date:  1979 Jul-Sep

8.  Abnormal amino-acid concentrations in the blood of patients with acquired immunodeficiency syndrome (AIDS) may contribute to the immunological defect.

Authors:  W Dröge; H P Eck; H Näher; U Pekar; V Daniel
Journal:  Biol Chem Hoppe Seyler       Date:  1988-03

Review 9.  A review of cancer cachexia and abnormal glucose metabolism in humans with cancer.

Authors:  J A Tayek
Journal:  J Am Coll Nutr       Date:  1992-08       Impact factor: 3.169

10.  [Amino acid uptake and release by colorectal cancer in man].

Authors:  J P Striebel; H D Saeger; R Ritz; H Leweling; E Holm
Journal:  Infusionsther Klin Ernahr       Date:  1986-04
View more
  7 in total

1.  Some amino acids levels: glutamine,glutamate, and homocysteine, in plasma of children with chronic kidney disease.

Authors:  Fatina I Fadel; Manal F Elshamaa; Rascha G Essam; Eman A Elghoroury; Gamila S M El-Saeed; Safinaz E El-Toukhy; Mona Hamed Ibrahim
Journal:  Int J Biomed Sci       Date:  2014-03

2.  Targeted metabolomics to understand the association between arsenic metabolism and diabetes-related outcomes: Preliminary evidence from the Strong Heart Family Study.

Authors:  Miranda J Spratlen; Maria Grau-Perez; Jason G Umans; Joseph Yracheta; Lyle G Best; Kevin Francesconi; Walter Goessler; Teodoro Bottiglieri; Mary V Gamble; Shelley A Cole; Jinying Zhao; Ana Navas-Acien
Journal:  Environ Res       Date:  2018-09-27       Impact factor: 6.498

3.  Low plasma glutamine in combination with high glutamate levels indicate risk for loss of body cell mass in healthy individuals: the effect of N-acetyl-cysteine.

Authors:  R Kinscherf; V Hack; T Fischbach; B Friedmann; C Weiss; L Edler; P Bärtsch; W Dröge
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

4.  Glutathione content and expression of proteins involved with glutathione metabolism differs in longissimus dorsi, subcutaneous adipose, and liver tissues of finished vs. growing beef steers.

Authors:  Jing Huang; Yang Jia; Qing Li; Kwangwon Son; Charles Hamilton; Walter R Burris; Phillip J Bridges; Arnold J Stromberg; James C Matthews
Journal:  J Anim Sci       Date:  2018-12-03       Impact factor: 3.159

5.  Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases.

Authors:  R Breitkreutz; A Babylon; V Hack; K Schuster; M Tokus; H Böhles; E Hagmüller; L Edler; E Holm; W Dröge
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

6.  Quantitative analysis of amino acid metabolism in liver cancer links glutamate excretion to nucleotide synthesis.

Authors:  Avlant Nilsson; Jurgen R Haanstra; Martin Engqvist; Albert Gerding; Barbara M Bakker; Ursula Klingmüller; Bas Teusink; Jens Nielsen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-27       Impact factor: 11.205

7.  Causes of early-onset type 1 diabetes: toward data-driven environmental approaches.

Authors:  Pierre Bougnères; Alain-Jacques Valleron
Journal:  J Exp Med       Date:  2008-12-22       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.